Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer

Medicine
Giuseppe Di LorenzoCarlo Buonerba

Abstract

Cabazitaxel provided a survival advantage compared with mitoxantrone in patients with castration-resistant prostate cancer refractory to docetaxel. Grade 3 to 4 (G3-4) neutropenia and febrile neutropenia were relatively frequent in the registrative XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC) trial, but their incidence was lower in the Expanded Access Program (EAP). Although cumulative doses of docetaxel are associated with neuropathy, the effect of cumulative doses of cabazitaxel is unknown. In this retrospective review of prospectively collected data, the authors assessed "per cycle" incidence and predictors of toxicity in the Italian cohort of the EAP, with a focus on the effect of cumulative doses of cabazitaxel.The study population consisted of 218 Italian patients enrolled in the cabazitaxel EAP. The influence of selected variables on the most relevant adverse events identified was assessed using a Generalized Estimating Equations model at univariate and multivariate analysis."Per cycle" incidence of G 3 to 4 neutropenia was 8.7%, whereas febrile neutropenia was reported in 0.9% of cycles. All events of febrile neutropenia occurred during the fi...Continue Reading

References

Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Mar 3, 2011·Cancer Chemotherapy and Pharmacology·Carlo BuonerbaGiuseppe Di Lorenzo
Oct 10, 2012·Current Drug Targets·Pasquale RescignoGiuseppe Di Lorenzo
Oct 10, 2012·Anti-cancer Drugs·Giuseppe Di LorenzoSabino De Placido
Nov 12, 2013·European Urology·Giuseppe Di LorenzoVincenzo Mirone
Feb 4, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Axel HeidenreichUNKNOWN European investigators
Jun 20, 2014·World Journal of Clinical Cases·Sabino De PlacidoGiuseppe Di Lorenzo
Jul 25, 2014·Therapeutic Advances in Medical Oncology·Daniel L Suzman, Emmanuel S Antonarakis
Oct 5, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J L MeiselD R Spriggs
Dec 11, 2014·Indian Journal of Cancer·V NoronhaK Prabhash
Mar 22, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H IzzedineB Escudier
Oct 1, 2014·Indian Journal of Cancer·A JoshiK Prabhash
Jun 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H IzzedineB Escudier

❮ Previous
Next ❯

Citations

Jun 27, 2017·The Prostate·Megan Crumbaker, Howard Gurney
Mar 3, 2018·Asia-Pacific Journal of Clinical Oncology·Thiru PrasannaCatriona M McNeil
Jul 18, 2019·Asia-Pacific Journal of Clinical Oncology·Loma Al-Mansouri, Howard Gurney
May 10, 2017·Annals of Neurology·Nathan P StaffAnthony J Windebank

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.